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ABSTRACT
Objective: To improve the understanding of the
determinants of prognosis and accurate risk
stratification in community-acquired pneumonia (CAP).
Design: Multicentre collaboration of prospective
cohorts.
Setting: 6 cohorts from the USA, Canada, Hong Kong
and Spain.
Participants: From a published meta-analysis of risk
stratification studies in CAP, the authors identified and
pooled individual patient-level data from six
prospective cohort studies of CAP (three from the
USA, one each from Canada, Hong Kong and Spain) to
create the International CAP Collaboration Cohort.
Initial essential inclusion criteria of meta-analysis were
(1) prospective design, (2) in English language, (3)
reported 30-day mortality and transfer to an intensive
or high dependency care and (4) minimum 1000
participants. Common baseline patient characteristics
included demographics, history and physical
examination findings, comorbidities and laboratory
and radiographic findings.
Primary and secondary outcome measures: This
paper reports the rationale, hypotheses and analytical
framework and also describes study cohorts and
patients. The authors aim to (1) compare the
prognostic accuracy of existing CAP risk stratification
tools, (2) assess patient-level determinants of
prognosis, (3) improve risk stratification by combined
use of scoring systems and (4) understand prognostic
factors for specific patient groups.
Results: The six cohorts assembled from 1991 to 2007
included 13 784 patients (median age 71 years, 54%
men). Aside from one randomised controlled study, the
remaining five were cohort studies, but all had similar
inclusion criteria. Overall, there was 0%e6% missing
data. A total of 6159 (44%) had severe pneumonia by
Pneumonia Severity Index class IV/V. Mortality at 30
days was 8% (1036). Admission to intensive care or
high dependency unit was also 8% (1059).
Conclusions: International CAP Collaboration Cohort
provides a pooled multicentre data set of patients with
CAP, which will help us to better understand the
prognosis of CAP.
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ARTICLE SUMMARY
Article focus
This paper reports the rationale, hypotheses and
analytical framework and also describes study
cohorts and patients. We aim to
- compare the prognostic accuracy of existing CAP
risk stratification tools;
- assess patient-level determinants of prognosis;
- improve risk stratification by combined use of
scoring systems;
- understand prognostic factors for specific patient
groups.
Key messages
- The International CAP Collaboration Cohort
(ICCC) as described in this report will be able
to provide better understanding of determinants
of outcomes in CAP. Examples of such develop-
ment include comparison of commonly and less
commonly known CAP severity scoring systems
and identification of characteristics of CAP
patients with poor outcome (30-day mortality)
despite non-severe status of severity score.
- In view of the large sample size, the ICCC cohort
will be able to provide the determinants of
outcomes in patient groups with specific condi-
tions such as cardiovascular and respiratory
diseases taking into account case mix and
individual prognostic indicators.
- The ICCC cohort will be of benefit to the CAP
research community and help define a future
agenda for research, as well as helping clinicians
make better clinical decisions for patients with CAP.
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BACKGROUND
Community-acquired pneumonia (CAP) is a common
medical condition, with an incidence of 11.6/1000
adults per year.1 It is one of the leading infectious causes
of death worldwide2e4 and accounts for substantial use
of healthcare resources.5 About 30% of patients with
CAP require hospital admission6 and up to one-fifth
require intensive care admission.7e9 The estimated costs
for treating pneumonia exceeded $9 billion per year in
the mid-1990s in the USA and exceed £441 million per
year in the UK.10 11
The management of CAP is challenging as the
outcome depends on multiple factors, such as patient
characteristics, care setting, type and virulence of the
infective agent, appropriate assessment and nature of
healthcare intervention, such as antibiotic administra-
tion, and intensive care support, and so on. Thus, clin-
ical determinants of outcomes in CAP have been the
subject of considerable research focus over the past few
decades.12e15 Several severity scores have been devel-
oped and validated widely, with the aim of guiding the
initial site of treatment (eg, home vs hospital; hospital
ward vs intensive care unit (ICU)) and appropriate level
of intervention, including choice and route of adminis-
tration of antibiotics.14e19 Better understanding of
determinants of patient outcomes in CAP may help
clinicians make better clinical decisions in future.
To date, there is no uniform agreement on the optimal
severity assessment tool or an agreed definition of the
term severe pneumonia.20 Pneumonia Severity Index
(PSI) was derived to identify patients with pneumonia
who are at low risk for short-term mortality and potential
candidates for outpatient care14 and widely used. The
British Thoracic Society endorses the use of CURB-65,
which is an extensively validated score since the publi-
cation of Lim et al’s15 work in stratifying risk of CAP
mortality using simple criteria. Its derivative, CRB-65, has
the advantage that it is simple and can be implemented
without laboratory investigations.21
Other scores that have since been developed include
SMART-COP,18 ADROP,22 CORB,23 SCAP,16 CURSI and
CURASI,24 and CURB-age,25 among others. SMART-COP
is a tool derived from an Australian study18; it uses
systolic blood pressure, multilobar involvement, albumin
levels, respiratory rate adjusted for age, heart rate,
confusion, oxygen level adjusted for age and arterial pH
to risk stratify for the need for intensive respiratory or
vasopressor support.18 The Japanese Respiratory Society
proposed the score ADROP to risk stratify, which has
been shown to yield similar results as CURB-65. ADROP
uses similar parameters as CURB-65, but there are
different cut-off values for age (>70 years for men,
>75 years for women), dehydration (blood urea
nitrogen (BUN) >210 mg/l), respiratory failure (SaO2
<90% or PaO2 <60 mm Hg), orientation disturbance
(confusion) and low blood pressure (systolic
<90 mm Hg or diastolic <60 mm Hg).22 SCAP was
developed in Spain, which suggested arterial pH <7.30,
systolic blood pressure <90 mm Hg, respiratory rate
>30/min, altered mental status, BUN >30 mg/dl,
oxygen arterial pressure <250 mm Hg, age >80 years
and multilobar/bilateral involvement to predict severe
pneumonia.16 CURSI/CURASI and CURB-age are
modified versions of CURB-65 and developed in the UK
where shock index (pulse rate divided by systolic blood
pressure with or without consideration of temperature)
is used instead of blood pressure and age in CURSI/
CURASI,24 and CURB-age used two cut-off points
for urea (>7 and >11 mmol/l) and age (65 and
85 years).25
Several studies have also directly compared different
pneumonia severity scales. Man et al26 directly compared
ARTICLE SUMMARY
Strengths and limitations of this study
- The ICCC is a multicentre/multiethnic cohort where all
collaborating groups defined pneumonia based on clinical
features and the presence of CXR evidence of pneumonia. The
major strengths of ICCC are prospective study design,
inclusion of CAP patients spanning across wide age range,
ethnicity, different healthcare settings and large sample size.
Potential areas of improvement in assessment of CAP might be
identification of at-risk patients with pneumonia who have been
initially assessed as non-severe CAP. With large sample size,
ICCC may provide an opportunity to identify characteristics of
such individuals. Based on this work, risk assessment may be
applied at more than one point in time in order to observe
temporal trends in recovery or deterioration in future CAP
research and clinical practice.
- There were multiple observers and data collections across
several centres. However, all cohorts followed the strict criteria
in data collection as described in table 1. Furthermore, the data
collected were objective measures such as age and urea level,
thereby ruling out potential observer bias. The process of care
between hospitals may be variable. There may be a variation in
clinical management between different hospitals and in
different healthcare setting between the various countries
such as there may be important variations in antibiotic use,
patterns of infective micro-organisms, care protocols and
treatment guidelines. Other limitations to consider are
biomarkers, healthcare provider and site characteristics. The
patients were enrolled into the study at different time periods.
However, this presents an opportunity to compare and contrast
different healthcare systems to better understand the variation
in healthcare setting and outcomes. Since all six studies used
the Pneumonia Severity Index (PSI) for risk stratification, this
can have implications, for example, patients who scored non-
severe at initial assessment (low PSI) but might have had
worse outcome are under-represented if such patients were
sent home. This could contribute to attenuation of estimates in
low PSI group. Nevertheless, it is possible that these patients
would have presented again to the medical centre if/when
deterioration occurred. Cohorts that only had data on CURB-
related variables and cohorts with smaller sample sizes were
not included in the ICCC, and this may introduce some degree
of selection bias. Nevertheless, this should not have any effect
on the internal relationship between the predictors and
outcomes of interest.
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the PSI, CURB-65 and CRB-65 in a cohort of
CAP patients in Hong Kong and found that PSI and
CURB-65 has similar performance at predicting 30-day
mortality. Capelastegui et al27 compared CURB-65 and
CRB-65 in a Spanish cohort; they also found similar
results using the two scales. Espana et al16 tested the
SCAP prediction rule in a Spanish cohort and found
that it was comparable in predictive value as both the
CURB-65 and PSI. Shindo et al22 compared the use of
ADROP and CURB-65 and found similar results. In the
derivation study of SMART-COP, the new score was
compared against CURB-65 and PSI and SMART-COP
had higher area under the receiver operator curve in
predicting need for intensive respiratory or vasopressor
support.18
While PSI and CURB indices were widely validated,
newly derived and less well-known CAP severity indices
have not been validated in a large sample. We created
the International CAP Collaboration Cohort (ICCC) to
assess patient-level determinants of prognosis and
compare the prognostic accuracy of existing pneumonia
risk stratification tools for patients hospitalised with CAP.
In this paper, we describe the six prospective CAP
cohorts from Asia, Europe and the North America
collaborating in ICCC.14 26e30 We also provide the
rationale, hypotheses and objectives of the study and
describe the characteristics of the combined cohort.
Finally, we discuss implications and the future direction
of research using this data set.
Rationale
While there have been some recent attempts to address
existing uncertainties through meta-analysis of severity
assessment tools,31 32 somewhat conflicting results arose
from the quality of studies included in these meta-anal-
yses. Loke et al31 included prospective studies only, and
Chalmers et al32 included both prospective and retro-
spective studies. Another limitation of these reviews is
that they had to rely on study-level aggregated data,
rather than individual patient data. Furthermore, it has
also been well recognised that severity measures do not
capture specific patient groups. For example, there has
been increasing concern with regard to suitability of
CURB-65 in both older and younger patients with
CAP.33 34 A recent comprehensive review by Singa-
nayagam et al20 and a study by Aliberti et al35 also high-
lighted the limitations of current established CAP
severity assessment criteria. Therefore, it is important to
better understand the determinants and outcomes of
CAP in a heterogeneous patient population to improve
the identification of patients with higher risk of poor
outcomes, taking into account of other important
factors, such as ethnicity, and healthcare systems. The
rationale of ICCC is to address the specific objectives
based on the hypotheses set out below by creating a CAP
cohort with large sample size with adequate power. This
paper aims to describe this ICCC cohort, which will test
the hypotheses and describe the pooled outcomes across
studies of different world regions.
Hypotheses and objectives
The hypotheses are as follows:
1. Different severity assessment tools for CAP have
different advantages and disadvantages.
2. It is possible to identify patients with CAP who have
been initially classified as having non-severe CAP by
one scoring system but who are at risk of death.
3. It is possible to apply more than one scoring system
sequentially to better identify CAP patients at high
risk of mortality.
4. There are patient characteristics, which can be
identified, which is associated with increased risk of
death in specific patient groups.
The main objectives of the ICCC, therefore, are to:
1. compare the accuracy (sensitivity, specificity, predictive
values and likelihood ratios) and discrimination
(receiver operating characteristics analyses) of existing
severity tools in predicting 30-day mortality and/or
ICU admission;
2. explore the characteristics of patients with pneu-
monia with poor outcome despite who scored non-
severe at initial assessment to identify relatively
high-risk group of patients;
3. examine whether using sequential assessment with
two separate rules (eg, one deployed as a triage test in
primary care or emergency department, followed by
a more specific test to guide inpatient management)
would improve predictive ability;
4. evaluate risk factors for prognosis and compare the
performance of existing severity rules in distinct
patient subgroups, for example, Nursing Home
Acquired Pneumonia, in those with chronic obstruc-
tive pulmonary disease (COPD) and people who are
immunocompromised.
METHODS
Our patient population was derived from previously
reported prospective CAP cohorts that were included in
a meta-analysis comparing the PSI and CURB-65.31 The
published CAP literature was reviewed as described in
Loke et al,31 and the largest cohorts (n>1000) meeting
the required standard of the review were invited to
participate.14 26e30 Each individual studies had prior
respective institutional research ethics approval for their
original data collection, and ICCC study was approved by
the Faculty of Medicine and Health Sciences Research
Ethics Committee, University of East Anglia, UK (Ref,
2011/2012-29).
The main inclusion criteria at individual patient level
were adults with diagnosis of pneumonia based on the
combination of clinical symptoms and signs of pneu-
monia (cough, sputum and fever) and radiological find-
ings of an opacity (or opacities) on chest radiograph
consistent with pneumonia. The coordinating centre
(CC) from the UK prepared a standardised data sheet,
and it was distributed to all collaborating centres for data
entry. The variables listed in the appendix 1 were
requested to all centres. The data were based on all the
variables needed to calculate the PSI score as well as the
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CURB-65 score, which also cover most of the variables
included in less well-known criteria. Therefore, those who
only reported CURB indices were not considered for
inclusion into the ICCC. We identified five research
groups who had relevant data on six cohorts, and all five
groups replied positively to the request. Additional base-
line information collected included patient comorbid-
ities, patient residence, antibiotic treatment they received
and the route of administration of antibiotics. Outcomes
such as admission to ICU with or without ventilation and
high dependency unit (HDU) were collected along with
the main outcome of 30-day mortality.
Anonymised patient data were entered by the partici-
pating centres and returned to the CC. Data were
checked and compiled by the research team at CC. Data
standardisation (eg, converting to same SI units) and
quality checking were centrally conducted. First, all the
data were combined into a single data file with the same
coding and units for each variable. Most dichotomous
variables values were coded as numbers (0¼no, 1¼yes)
and blanks for missing values. In particular, urea values
were converted to BUN by multiplying by a factor of 2.8.
For each variable, the values were checked for errors by
considering the maximum and minimum values or values
that are beyond the expected/plausible range. Finally,
some variables were combined to generate new variables,
including any ICU variable (ICU with ventilation and
ICU without ventilation combined) and any ICU/HDU
variable (any ICU and HDU admission combined).
Analytical approach
Data are presented descriptively for individual cohorts as
well as the ICCC (combined cohort) for the purposes of
the current report. We pooled the cohorts by simple
aggregation of individual patient data rather than using
any form of weighting or meta-analytic techniques to
combine the study and explore the heterogeneity. We
present median (IQR) values for non-normally distributed
data and mean (SD) for normally distributed continuous
data and numbers (percentages) for categorical data. We
analysed the data using STATA V.10.0 (2009, StataCorp).
At present, we have simply pooled the data and
describe the cohort in this rationale paper, but expect to
use meta-analytic techniques and individual patient data
approaches to better explore between cohort heteroge-
neity, such as ethnicity and healthcare setting, and how it
may relate to outcomes. Furthermore, we should be able
to explore more general issues such as how best to deal
with missing data in large clinical samples (ie, complete
case, dummy variables for missing data, imputation).
Overview of study designs and methods
Overall, five research teams responsible for assembling
six potentially eligible cohorts were invited to partici-
pate. In all six cohorts, CAP was defined based on the
presence of clinical symptoms and signs of pneumonia,
and the presence of radiographic pulmonary opacity/
opacities consistent with CAP, as interpreted by either
the treating physician or by a staff radiologist. Patients
recruited were those with CAP first presenting to an
outpatient department (cohort 3) or the emergency
departments (all other cohorts) (see table 1). In general,
all cohorts used similar inclusion criteria with similar
reliable methods to diagnose pneumonia combing both
clinical evidence and radiological features of pneu-
monia. The ascertainment of survival at 30 days varied
from telephone interviews to record linkage using
administrative healthcare databases. Four of six cohorts
recruited participants from multiple centres, while two
(Hong Kong and Spain) involved only a single centre.
Baseline patient characteristics
Table 2 shows the patient-related sample characteristics.
The median ages of cohorts ranged between 59 and
76 years at the time of enrolment (median age in this
pooled data set is 71 years; IQR 52e80 years), of which
54% were men. Data on race and ethnicity were available
in four cohorts. Data on smoking and alcohol use were
available for 54% and 74%, respectively, of the patients.
Only 1% of the ICCC patient population has missing
data for whether they were admitted from nursing home
facility or elsewhere.
Table 3 shows the prevalence of comorbid conditions.
The most commonly captured comorbid conditions
were COPD, coronary artery disease and stroke/cere-
brovascular disease. Five cohorts have available data on
background dementia (total n¼832 of 12 021, 0.07%),
and all have information on presence or absence of
malignant disease (total n¼912 of 13 744, 0.07%).
Table 4 shows clinical and laboratory characteristics.
There were no material differences in key clinical char-
acteristics among cohorts, except for prevalence of
confusion, which was relatively lower in cohort 1, and
mean systolic blood pressure that was notably higher in
cohort 5 where the median age of the cohort was rela-
tively higher than other cohorts. All six studies used the
PSI for risk stratification, and two cohorts (cohorts 2 and
5) also used the CURB-65. Overall, as defined within
each cohort, 6159 (44%) patients had severe pneumonia
by PSI class IV/V.
All cohorts had complete data on 30-day mortality
outcome but recorded ICU and HDU admission in
various format/coding. Generally, all cohorts have
complete data for ICU and/or HDU outcome (only 1
with missing data). The 30-day mortality ranged between
4% and 11%, with an overall ICCC 30-day mortality of
8% (n¼1036). Admission to intensive care or HDU was
also 8% (1059).
Missing data and data that were not recorded
Overall, across all cohorts, there were 12.2% of data that
were requested from each cohort that were not recorded
andmaximum of 6% of data were missing (see appendix 2).
DISCUSSION
The ICCC is a multicentre/multiethnic cohort where
all collaborating groups defined pneumonia based on
clinical features and the presence of CXR evidence of
4 Myint PK, Kwok CS, Majumdar SR, et al. BMJ Open 2012;2:e001030. doi:10.1136/bmjopen-2012-001030
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pneumonia. The major strengths of ICCC are prospective
study design, inclusion of CAP patients spanning across
wide age range, ethnicity, different healthcare settings
and large sample size. Potential areas of improvement in
assessment of CAP might be identification of at-risk
patients with pneumonia who have been initially assessed
as non-severe CAP. With large sample size, ICCC may
provide an opportunity to identify characteristics of such
individuals. Based on this work, risk assessment may be
applied at more than one point in time in order to
observe temporal trends in recovery or deterioration in
future CAP research and clinical practice.
Furthermore, despite there being some degree of
missing data, the large sample size of ICCC enables us to
examine the CAP outcome in patient populations with
specific characteristics of interest. Examples of such
Table 3 Distribution of selected comorbid conditions in individual collaborating cohorts and the combined cohort
Comorbidities Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 Cohort 6 ICCC
COPD
Yes e 569 (27.0) 588 (25.7) 638 (18.7) 10 (1.0) 1034 (32.3) 2839 (20.5)
No e 1541 (73.0) 1687 (73.8) 2777 (81.3) 1004 (99.0) 2167 (67.7) 9176 (66.1)
Missing/NA 1847 (100) 0 (0) 12 (0.5) 0 (0) 0 (0) 0 (0) 1859 (13.4)
Asthma
Yes e e e 440 (12.9) 1 (0.01) e 441 (3.2)
No e e e 2975 (87.1) 1013 (99.9) e 3988 (28.7)
Missing/NA 1847 (100) 2110 (100) 2287 (100) 0 (0) 0 (0) 3201 (100) 9445 (68.1)
Pleural effusion
Yes 201 (10.9) 219 (10.4) 204 (8.9) 745 (21.8) 112 (11.0) 461 (14.4) 1942 (14.0)
No 1523 (82.5) 1891 (89.6) 1976 (86.4) 2670 (78.2) 902 (89.0) 2715 (84.8) 11 677 (84.2)
Missing/NA 123 (6.7) 0 (0) 107 (4.7) 0 (0) 0 (0) 25 (0.8) 255 (1.8)
Heart failure
Yes 294 (15.9) 163 (7.7) 253 (11.1) 727 (21.3) 121 (11.9) 427 (13.3) 1985 (14.3)
No 1429 (77.4) 1947 (92.3) 2030 (88.8) 2688 (78.7) 893 (88.1) 2774 (86.7) 11 761 (84.8)
Missing/NA 124 (6.7) 0 (0) 4 (0.2) 0 (0) 0 (0) 0 (0) 128 (0.9)
Coronary artery disease
Yes e 215 (10.2) 406 (17.8) 910 (26.6) e 667 (20.8) 2198 (15.8)
No e 1895 (89.8) 1880 (82.2) 2505 (73.4) e 2534 (79.2) 8814 (63.5)
Missing/NA 1847 (100) 0 (0) 1 (<0.1) 0 (0) 1014 (100) 0 (0) 2862 (20.6)
Cerebrovascular disease
Yes 150 (8.1) 200 (9.5) 210 (9.2) 306 (9.0) 143 (14.1) 267 (8.3) 1276 (9.2)
No 1574 (85.2) 1910 (90.5) 2076 (90.8) 3109 (91.0) 871 (85.9) 2934 (91.7) 12 474 (89.9)
Missing 123 (6.7) 0 (0) 1 (<0.1) 0 (0) 0 (0) 0 (0) 124 (0.9)
Liver disease
Yes 34 (1.8) 76 (3.6) 33 (1.4) 117 (3.4) 17 (1.7) 28 (0.9) 305 (2.2)
No 1690 (91.5) 2034 (96.4) 2251 (98.6) 3298 (96.6) 997 (98.3) 3173 (99.1) 13 443 (96.9)
Missing 123 (6.7) 0 (0) 3 (0) 0 (0) 0 (0) 0 (0) 126 (0.9)
Renal disease
Yes 89 (4.8) 160 (7.6) 153 (6.7) 490 (14.3) 106 (10.5) 108 (3.4) 1106 (8.0)
No 1635 (88.5) 1950 (92.4) 2131 (93.2) 2925 (85.7) 908 (89.5) 3093 (96.6) 12 642 (91.1)
Missing 123 (6.7) 0 (0) 3 (0.1) 0 (0) 0 (0) 0 (0) 126 (0.9)
Cancer
Yes 87 (4.7) 131 (6.2) 109 (4.8) 499 (14.6) 1 (0.1) 85 (2.7) 912 (6.6)
No 1637 (88.6) 1979 (93.8) 2171 (94.9) 2916 (85.4) 1013 (99.9) 3116 (97.3) 12 832 (92.5)
Missing 123 (6.7) 0 (0) 7 (0.3) 0 (0) 0 (0) 0 (0) 130 (0.9)
Diabetes
Yes e 309 (14.6) 235 (10.3) 190 (5.6) e 625 (19.5) 1359 (9.8)
No e 1801 (85.4) 2052 (89.7) 3225 (94.4) e 2576 (80.5) 9654 (69.6)
Missing/NA 1847 (100) 0 (0) 0 (0) 0 (0) 1014 (100) 0 (0) 2861 (20.6)
Dementia
Yes e 276 (13.1) 141 (6.2) 265 (7.8) 22 (2.2) 128 (4.0) 832 (6.0)
No e 1834 (86.9) 2141 (93.6) 3150 (92.2) 992 (97.8) 3072 (96.0) 11 189 (80.6)
Missing/NA 1847 (100) 0 (0) 5 (0.2) 0 (0) 0 (0) 1 (<0.1) 1853 (13.4)
Seizure
Yes e e 91 (4.0) 151 (4.4) 2 (0.2) e 244 (1.8)
No e e 2196 (96.0) 3264 (95.6) 1012 (99.8) e 6272 (45.9)
Missing/NA 1847 (100) 2110 (100) 0 (0) 0 (0) 0 (0) 3201 (100) 7158 (52.3)
Values presented are number (%). Percentages may not sum to 100% due to rounding.
COPD, chronic obstructive pulmonary disease; ICCC, International Community-Acquired Pneumonia (CAP) Collaboration Cohort; NA, not available.
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groups include those with COPD and cancer and
patients admitted from nursing homes. Another impor-
tant aspect in estimating prognosis in patients with CAP
is with regard to older people whose mortality outcome
is substantially higher. The ICCC provides a large
prospective cohort of older people aged 65 years and
older and subset of extremely old patients (aged 85
+ years). The usefulness of different assessment scores
and impact of co-existing comorbidities can be further
examined to enhance the understanding of prognosis in
this growing patient population due to current and
expected demographics.
In addition, there have been studies that evaluate
mortality risk scores in specific patient populations with
CAP. The elderly represent a distinct population group,
and the SOAR score has been developed specifically to
predict mortality.36 The MELD-CAP score has been show
to outperform CURB-65 and PSI in patients with
cirrhosis.37 For patients admitted to the ICUs, the PIRO
score has been developed.19 There have also been other
studies, which look at predictive value of pneumonia
severity scores in other populations, including patients
with H1N1 infection,38 HIV infection39 and chronic
kidney disease.40 Therefore, ICCC also provides a large
cohort, which may be able to address the value of different
pneumonia severity scores in specific populations.
Our study has limitations. There were multiple
observers and data collections across several centres.
However, all cohorts followed the strict criteria in data
collection as described in table 1. Furthermore, the data
collected were objective measures such as age and urea
level, thereby ruling out potential observer bias. The
process of care between hospitals may be variable. There
may be a variation in clinical management between
different hospitals and in different healthcare setting
between the various countries such as there may be
important variations in antibiotic use, patterns of infec-
tive micro-organisms, care protocols and treatment
guidelines. Other limitations to consider are biomarkers,
healthcare provider and site characteristics. The patients
were enrolled into the study at different time periods.
However, this presents an opportunity to compare and
contrast different healthcare systems to better under-
stand the variation in healthcare setting and outcomes.
Since all six studies used the PSI for risk stratification,
this can have implications, for example, patients who
scored non-severe at initial assessment (low PSI) but
might have had worse outcome are under-represented if
such patients were sent home. This could contribute to
attenuation of estimates in low PSI group. Nevertheless,
it is possible that these patients would have presented
again to the medical centre if/when deterioration
occurred. Cohorts that only had data on CURB-related
variables and cohorts with smaller sample sizes were not
included in the ICCC, and this may introduce some
degree of selection bias. Nevertheless, this should not
have any effect on the internal relationship between the
predictors and outcomes of interest.T
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In summary, the ICCC as described in this report will
be able to provide better understanding of determinants
of outcomes in CAP. Examples of such development
include comparison of commonly and less commonly
known CAP severity scoring systems and identification of
characteristics of CAP patients with poor outcome (30-
day mortality) despite non-severe status of severity score.
In view of the large sample size, the ICCC cohort will be
able to provide the determinants of outcomes in patient
groups with specific conditions such as cardiovascular
and respiratory diseases taking into account case mix
and individual prognostic indicators. The ICCC cohort
will be of benefit to the CAP research community and
help define a future agenda for research, as well as
helping clinicians make better clinical decisions for
patients with CAP.
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APPENDIX 1
Variables requested from each collaborating cohort
< Age (continuous)
< Gender (male/female)
< BMI
< Race
< Smoking
< Alcohol
< Illicit drug use
< Altered mental status (yes/no)
< Altered mental status (abbreviated mental test score if measured as
continuous)
< Urea or BUN levels (continuous)
< BUN category (as per PSI using cut-off point of 30; #30 vs >30)
< Respiratory rate (continuous)
< Respiratory rate (categorical as per PSI using cut-off point of 30;
<30 vs $30)
< Systolic blood pressure (continuous)
< Systolic blood pressure (categorical as per PSI using cut-off point of
90; <90 vs $90)
< Diastolic blood pressure (continuous) (for CURB-65/CRB calcula-
tion)
< Pneumonia Severity Index score (sum)
Other parameters in Pneumonia Severity Index
< Residence (categorical data with coding)
< Nursing home residence (yes/no)
< Renal disease (yes/no)
< Liver disease (yes/no)
< CHF (yes/no)
< Cerebrovascular disease (yes/no)
< Neoplasia (yes/no)
< Temperature (continuous)
< Temperature (categorical as per PSI; <35 or $40 vs 35e40)
< Heart rate (continuous)
< Heart rate (categorical as per PSI; <125 vs $125)
< pH (continuous)
< pH (categorical as per PSI; <7.35 vs $7.35)
< PO2 (continuous)
< PO2 (categorical as per PSI; <60 vs $60)
< Saturation (continuous)
< Saturation (categorical as per PSI using cut-off point of 90; <90 vs
$90)
< Sodium (Na) (continuous)
< Sodium (categorical as per PSI using cut-off point of 130; <130 vs
$130)
< Haematocrit (continuous)
< Haematocrit (categorical as per PSI using cut-off point of 30; <30 vs
$30)
< Glucose (continuous)
< Glucose (categorical as per PSI using cut-off point of 250; #250 vs
>250)
< Pleural effusion (yes/no)
< Comorbidities (others)
< Antibiotic use (in text)
< Route (IV/oral)
< Whether they completed the study (lost to follow-up) (yes/no)
< Whether they died during the 30-day follow-up (yes/no)
< Whether they died during admission (in hospital death) (yes/no)
< Date of death (dd/mm/yyyy format)
< Death within 30 days (yes/no)
< Whether they were admitted to intensive care unit (for ventilation)
(yes/no)
< Whether they were admitted to high dependency unit (yes/no)
< Whether they were admitted to ICU without ventilatory support (yes/
no)
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APPENDIX 2
Data not recorded or missing
Variable
Cohort 1
(n[1847)
Cohort 2
(n[2110)
Cohort 3
(n[2287)
Cohort 4
(n[3415)
Cohort 5
(n[1014)
Cohort 6
(n[3201)
Not
recorded Missing
Not
recorded Missing
Not
recorded Missing
Not
recorded Missing
Not
recorded Missing
Not
recorded Missing
Age N 0 N 0 N 0 N 0 N 0 N 0
Sex N 0 N 0 N 0 N 0 N 0 N 0
Ethnicity N 0 Y NA N 0 N 0 N 0 N 1
Smoking N 1523 N 1607 N 19 N 0 N 0 Y NA
Alcohol N 19 N 20 N 368 N 0 N 6 Y NA
Nursing home N 138 N 0 N 0 N 0 N 0 N 0
COPD Y NA N 0 N 12 N 0 N 0 N 0
Asthma Y NA Y NA Y NA N 0 N 0 Y NA
Pleural effusion N 123 N 0 N 107 N 0 N 0 N 25
Heart failure N 124 N 0 N 4 N 0 N 0 N 0
CAD Y NA N 0 N 1 N 0 Y NA N 0
CVD N 123 N 0 N 1 N 0 N 0 N 0
Liver disease N 123 N 0 N 3 N 0 N 0 N 0
Renal disease N 123 N 0 N 3 N 0 N 0 N 0
Cancer N 123 N 0 N 7 N 0 N 0 N 0
Diabetes Y NA N 0 N 0 N 0 Y NA N 0
Dementia Y NA N 0 N 5 N 0 N 0 N 1
Seizure Y NA Y NA N 0 N 0 N 0 N 0
Confusion N 101 N 0 N 2 N 0 N 0 N 0
BUN N 127 N 0 N 787 N 482 N 0 N 683
Urea Y NA N 0 N 787 N 485 N 0 N 683
Resp N 8 N 0 N 482 N 121 N 0 N 683
sBP N 129 N 0 N 267 N 41 N 0 N 9
dBP N 4 N 46 N 351 N 50 N 0 N 45
Temp Y NA N 0 N 269 N 46 N 0 N 33
HR N 1 N 0 N 316 N 14 N 0 N 4
PaO2 N 123 N 60 N 1328 N 1137 N 1 N 2608
pH Y NA N 58 N 1328 N 1167 N 0 N 2608
Glucose N 190 N 2 N 828 N 428 N 0 N 691
Na N 171 N 0 N 792 N 143 N 1 N 677
ICU/vent Y NA N 0 N 0 N 0 N 0 Y NA
ICU/any N 0 N 0 N 0 N 0 N 0 N 9
HDU Y NA N 0 Y NA Y NA N 1 Y NA
ICU/HDU N 0 N 0 N 0 N 0 N 0 N 0
Death N 0 N 0 N 0 N 0 N 0 N 56
BUN, blood urea nitrogen; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular disease; dBP,
diastolic blood pressure; HDU, high dependency unit; HR, heart rate; ICU, intensive care unit; N, no; NA, not applicable; sBP, systolic blood
pressure; Y, yes.
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